Novotech, Quintiles and Pharma firms debate pros and cons
April 4, 2005 by admin
Filed under Company News, Company News 2005
April 4, 2005 – Dallas, Texas — Novotech, Australia’s leading contract research organization (CRO), today announced that Novotech CEO Alek Safarian will debate the pros and cons of outsourcing globally at the 14th Annual Partnership with CROs and other Outsourcing Providers (April 4-6 Dallas). Other panelists include executives from pharma firms, and Quintiles Transnational.
The panelists will debate the pros and cons around the variety of ways a company might outsource globally including:
- Mixed model management
- Outsourcing to global CRO
- Outsourcing to local CRO
- Outsourcing to niche CROs
- Outsourcing to regional providers versus per country
- Outsourcing a trial versus a program
Alternative (hybrid) models for outsourcing a multinational clinical trial program
Session: Debating the Pros and Cons of Outsourcing Globally Using a Variety of Outsourcing Models
Date: Tuesday, April 5, 2005
Time: 4:00pm
Panelists:
Alek Safarian, CEO
NOVOTECH (AUSTRALIA) PTY, LTD
Mark A. Lanfear, Associate Director, Clinical Affairs
KV PHARMACEUTICAL COMPANY
Ed Campanaro, Executive Director, Clinical Operations
CUBIST PHARMACEUTICALS
Peter Payne, Vice President of Corporate Development
QUINTILES TRANSNATIONAL
About Novotech – Unsurpassed Local Knowledge and Network:
Increasingly, U.S. companies are turning to Australia to expedite the pace, and reduce the cost, of clinical trials, while maintaining the high standard of research that U.S. authorities demand. A 2001 Ernst and Young benchmarking study found that clinical research costs may be as much as 30 percent lower in Australia than in the United States and Europe.
In addition, Australian regulatory procedures often enable a trial to begin in as little as 2-3 months from the initiation of the approval process. This compares favorably to usual timelines in major Western countries.
As the largest independent CRO in Australia, Novotech offers a level of flexibility and local knowledge that is virtually unmatched among other contract research organizations in the region. This has helped Novotech develop a strong client base in the United States and Europe.
Headquartered in Sydney, Novotech is focused on the Australian and New Zealand markets but has worldwide reach through the company’s subsidiary in the United Kingdom and through key external partnerships and strategic alliances in North America and other regions.
